An observational study in Tricuspid Regurgitation (TR), sponsored by Francesco Maisano. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Francesco Maisano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Tricuspid Valve Insufficiency with a site in Italy — 16 open to participants now, 19 under way, none of them phase 3. Tricuspid Valve Insufficiency · Italy.
Among the 32 studies in Tricuspid Valve Insufficiency with a site in Italy, this one is the 17th largest by planned enrollment of the 23 observational ones that give a count, is one of 4 that started in 2025, is one of 23 observational ones, reaches primary completion later than 12 of the 18 other live ones, and was the 30th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →16 of the 32 studies in Tricuspid Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Italy, United States, France and 2 more countries
Ages 18+
Centro Cardiologico Monzino · Sites in Italy
Ages 18+ · Healthy volunteers
Azienda Ospedaliero, Universitaria Pisana · Sites in Italy
Ages 18+
Medical University of Vienna · Sites in Italy, Austria, Germany and 1 more country
Ages 18+
Edwards Lifesciences · Sites in Italy, Germany, Greece and 3 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 150 is below the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 98 across the 9 interventional studies, 250 across the 23 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Francesco Maisano as lead sponsor.
Francesco Maisano has 1 study filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Tricuspid Valve Insufficiency with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825898Ottawa Heart Institute Research CorporationOutcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment | 2026-12 |
| NCT05820516Azienda Ospedaliero, Universitaria PisanaPatients With Severe TrIcuspid Regurgitation After triCvALve System Implantation | 2026-12 |
| NCT06093828TriFlo Cardiovascular, Inc.Transcatheter Treatment of Tricuspid Valve Regurgitation | 2027-01 |
| NCT06902922Francesco MaisanoImpact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function | 2027-03-31 |
| NCT07617974Centro Cardiologico MonzinoNatural History of Atrial Fibrillation-Induced Tricuspid Valve Remodeling in the Absence of Significant Tricuspid Regurgitation: A Three-Dimensional Echocardiographic Study | 2027-05-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 32 studies in Tricuspid Valve Insufficiency with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Tricuspid regurgitation (TR) is gaining increasing attention within the cardiological community due to its poor prognosis, challenging clinical presentation and difficult treatment.
TR causes decreased forward cardiac output and increased intravascular pressure upstream, which lead to peripheral oedema, ascites, hepatic congestion and kidney failure.
The microbiota is also getting increasing attention and changes in microbiota have been already associated with cardiovascular disease.
The impact of hemodynamic effects of TR on the gut microbiota however is still unknown.
Patients affected by TR frequently complain abdominal distension and anorexia. We hypothesize that, due to increased venous congestion, TR may induce impaired gut function with modification in the microbiota and that TR correction may induce reverse changes.
This study will enroll patients treated with Transcatheter Tricuspid Edge-to-Edge Repair (T-TEER) at the Valve Center of San Raffaele Hospital due to severe TR.
In addition to the standard of care, before T-TEER, for all patients 2 additional blood samples, 1 urine and 1 fecal sample will be collected.
3 months after the procedure, all patients will be re-assessed at the Valve Center outpatient clinic as standard of care. At this stage for all patients 2 blood samples, 1 urine and 1 fecal sample will be collected again for the purpose of the study. The microbiota metabolites of patients after 3 months from the procedure will be compared to those at baseline according to the degrees of residual TR.
To assess the reproducibility of the microbiota results and to explore an intrinsic short-term variation in microbiome composition within single patients, a subgroup of 30 patients will undergo a low intervention substudy repeating the measurements (2 blood, 1 urine and 1 fecal) within 10 days, both at baseline and at follow-up.
Adult patients with TR ≥ severe who will undergo T-TEER
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients, able to sign the Informed Consent Form, with TR ≥ severe who will be treated with T-TEER
Gut Microbiota Changes
The microbiota metabolites production in patients affected by severe TR and their changes after transcatheter TR correction will be measured at 3-months, compared to baseline, in terms of c differential abundance in microbiota metabolites, according to residual TR groups
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Mar 2027, 24 months later.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →